A Hebrew University startup company, Atox Bio, has developed a promising treatment for flesh eating bacteria. Atox Bio’s lead product, AB103, is a novel immunomodulator discovered by Professor Raymond Kaempfer and Dr. Gila Arad.

Atox Bio, which was established by Yissum,  has just raised $23 million to foster clinical trials.

To read more about Atox Bio and their accomplishment visit  Dow Jones, Ha’aretz and Israel21C.